tek

Merestinib dihydrochloride (LY2801653 dihydrochloride) is an orally available kinase inhibitor with antitumor activity that inhibits MET, AXL, RON, and MKNK1/2, and inhibits the growth of NTRK fusion-carrying tumors.

NVP-AEW541 (AEW541), a potent inhibitor of IGF-1R(IC50=150 nM) and InsR(IC50=140 nM), exhibits excellent efficiency and specificity for IGF-1R in a cell-based assay.

Ditekiren is a renin inhibitor with orally active.

Aletekitug is a humanized antibody that targets IL-18. Alekitug binds to free IL-18, thereby blocking its interaction with the IL-18 receptor α/β heterodimer and preventing receptor activation. This inhibits the release of pro-inflammatory cytokines, reduces the infiltration of immune cells at sites of inflammation, and exerts an anti-inflammatory effect. Alekitug can be used in research on inflammatory conditions such as inflammatory bowel disease.

Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.

Mitapivat (PKR-IN-1), also known as PKM2 activator 1020 is a PKM2 activator (pyruvate kinase activator) for the treatment of pyruvate kinase deficiency.

4-Hydroxy-3-Nitrophenyl Acetate-KLH is a hapten-protein conjugate serving as a carrier protein for immunological studies. 4-Hydroxy-3-Nitrophenyl Acetate-KLH facilitates the generation of hapten-specific immune responses and is frequently employed to investigate antibody production, antigen presentation, and immune system activation mechanisms.

Disodium monofluorophosphate (NSC248) is a competitive inhibitor of pyruvate kinase and alkaline phosphatase, which also irreversibly inhibits phosphorylase phosphatase.

Trelagliptin succinate (SYR-472 succinate) is a long-acting inhibitor of dipeptidyl peptidase-4 (DPP-4), being developed for the treatment of type 2 diabetes (T2D).

Matrine (Vegard), an alkaloid isolated from the Sophora genus, acts as a kappa opioid receptor agonist.

Trelagliptin (SYR-472) is a highly specific, long-acting DPP-4 inhibitor.

DL-Serine is a non-essential amino acid and a natural ligand and allosteric activator of pyruvate kinase M2.

Ocifisertib hydrochloride (CFI-400945 hydrochloride) is the hydrochloride salt form of Ocifisertib. It is an orally bioavailable PLK4 inhibitor with a Ki of 0.26 nM and an IC50 of 2.8 nM. This compound inhibits the growth of multiple cancer cell types, causes cell cycle arrest at the G2/M phase, and induces apoptosis. In mouse models, Ocifisertib hydrochloride exhibits antitumor activity.

CFI-400945 is an orally active, potent, and selective inhibitor of polo-like kinase 4.

Pyridone 6 (JAK Inhibitor)(CMP 6) is a potent and selective inhibitor of JAK1 (IC50=15 nM, murine JAK1), JAK2 (IC50=1 nM), JAK3 (Ki=5 nM), and Tyk2 (IC50=1 nM); displaying significantly weaker affinities (130 nM to 10 mM) for other protein tyrosine kinases.

Ocifisertib (CFI-400945 free base) is a potent, selective and orally active inhibitor of polo-like kinase 4 (PLK4; Ki value 0.26 nM; IC50 value 2.8 nM).

(+)-Shikonin (Anchusa acid) is a natural product, a TMEM16A chloride channel inhibitor (IC50=6.5 μM) and selective PKM2 inhibitor. (+)-Shikonin exhibits antitumor, anti-inflammatory and wound healing activities.

PKR-IN-2 is a activator of pyruvate kinase (PKR).

NG 52 (NG-52) is a cell-permeable, reversible, and ATP-compatible inhibitor of the cell cycle-regulating kinase Cdc28p and the related Pho85p kinase.

Pantothenate Kinase Inhibitor (PANKi) is a reversible inhibitor of pantothenate kinase (PanK; IC50s = 70, 92, and 25 nM for PanK1β, PanK2, and PanK3, respectively), the rate-limiting enzyme in the synthesis of coenzyme A .1It binds to the ATP-PanK3 complex with an apparent binding constant of 300 nM and exhibits mixed-type inhibition with respect to ATP and pantothenate. PANKi inhibits CoA biosynthesis in C3A cells (IC50= 0.9 μM) with no effect on cell viability when used at concentrations up to 8 μM. PANKi (5 μM) synergizes with BSO to induce ferroptosis in PANC-1 cells and sensitizes the cells to imidazole ketone erastin-induced ferroptosis.2 1.Sharma, L.K., Leonardi, R., Lin, W., et al.A high-throughput screen reveals new small-molecule activators and inhibitors of pantothenate kinasesJ. Med. Chem.58(3)1563-1568(2015) 2.Badgley, M.A., Kremer, D.M., Maurer, H.C., et al.Cysteine depletion induces pancreatic tumor ferroptosis in miceScience368(6486)85-89(2020)

PKM2-IN-1 (compound 3k) exhibits inhibitory activity against PKM2 with an IC50 of 2.95 μM, while the IC50 for PKM1 is 4-5 times higher.

Telithromycin is a semisynthetic 14-membered macrolide antibiotic and erythromycin derivative that binds to the 50S subunit of the 70S bacterial ribosome, inhibits bacterial protein synthesis, and exhibits antimicrobial activity against a wide range of gram-positive and gram-negative bacteria for the treatment of mild to moderate respiratory infections.

PZ-2891 is an orally bioavailable, brain-penetrant pantothenate kinase (PANK) modulator, with an IC50 of 1.3 nM for hPANK3.

Pantothenate Kinase-IN-1 (Compound 1) functions as a modulator of Pantothenate Kinase (PANK), exhibiting an inhibition concentration (IC50) value of 0.51 μM against PANK3. It demonstrates notable ligand efficiency with a LipE value of 2.8 [1].